Journal Home > Volume 2 , Issue 1
Brain Science Advances 2016, 2(1): 46-49 https://doi.org/10.18679/CN11-6030_R.2016.012
Review Article | Open Access | Issue | Published: 01 March 2016

Effects of the APOE ε4 allele on therapeutic response in Alzheimer’s disease

Show Author's Information I Chien1,  Yuanhan Yang1,2,3( )
Department of Neurology, Kaohsiung Medical University, Kaohsiung, Taiwan, China
Department of Master’s Program in Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, China
Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan, China
Keywords:
Alzheimer’s disease, apolipoprotein E
Cite this article:
Chien I, Yang Y. Effects of the APOE ε4 allele on therapeutic response in Alzheimer’s disease. Brain Science Advances, 2016, 2(1): 46-49. https://doi.org/10.18679/CN11-6030_R.2016.012
Download citation
EndNote(RIS)
BibTeX

275

Views

8

Downloads

Citations

0

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

Abstract Full text About this article

The apolipoprotein E (APOE) ε4 allelle is a well-established risk factor for cognitive decline. Racial factors may mitigate its effects. However, APOE ε4 has similar effects even among different racial groups. The APOE genotype in patients with Alzheimer’s disease may influence therapeutic decisions.


menu
Abstract
Full text
Outline
About this article

Effects of the APOE ε4 allele on therapeutic response in Alzheimer’s disease

Show Author's information I Chien1, Yuanhan Yang1,2,3( )
Department of Neurology, Kaohsiung Medical University, Kaohsiung, Taiwan, China
Department of Master’s Program in Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, China
Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan, China

Abstract

The apolipoprotein E (APOE) ε4 allelle is a well-established risk factor for cognitive decline. Racial factors may mitigate its effects. However, APOE ε4 has similar effects even among different racial groups. The APOE genotype in patients with Alzheimer’s disease may influence therapeutic decisions.

Keywords: Alzheimer’s disease, apolipoprotein E

References(29)

[1]
Wenk GL. Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry 2003, 64(Suppl 9): 7–10.
Google Scholar
[2]
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261(5123): 921–923.
DOI Google Scholar
[3]
Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994, 53(5): 429–437.
DOI Google Scholar
[4]
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90(5): 1977–1981.
DOI Google Scholar
[5]
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997, 278(16): 1349–1356.
Google Scholar
[6]
Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Stopford C, Julien C, Thompson J, Payton A, Pickering-Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DMA. Apolipoprotein E ε4 allele frequency and age at onset of Alzheimer’s disease. Dement Geriatr Cogn Disord 2007, 23(1): 60–66.
DOI Google Scholar
[7]
Resnick SM, Bilgel M, Moghekar A, An Y, Cai Q, Wang MC, Thambisetty M, Prince JL, Zhou Y, Soldan A, Wong DF, O’Brien RJ, Ferrucci L, Albert MS. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging 2015, 36(8): 2333– 2339.
DOI Google Scholar
[8]
Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ. Decline in verbal memory during preclinical Alzheimer’s disease: Examination of the effect of APOE genotype. J Int NeuropsycholSoc 2002, 8(7): 943–955.
DOI Google Scholar
[9]
Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. Neurobiol Aging 2011, 32(1): 63–74.
DOI Google Scholar
[10]
Thorvaldsson V, Nordlund A, Reinvang I, Blennow K, Zetterberg H, Wallin A, Johansson B. Memory in individuals with mild cognitive impairment in relation to APOE and CSF Aβ42. Int Psychogeriatr 2010, 22(4): 598–606.
DOI Google Scholar
[11]
Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991, 12: 383–388.
DOI Google Scholar
[12]
Buee L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000, 33(1): 95–130.
DOI Google Scholar
[13]
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2012, 2: 700.
DOI Google Scholar
[14]
Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Hartikainen P, Hanninen T, Ryynanen M, Riekkinen PJ. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer’s disease: Relation to apolipoprotein E polymorphism. Neurology 1996, 46(2): 413–419.
DOI Google Scholar
[15]
Wolk DA, Dickerson BC. The Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci USA 2010, 107(22): 10256–10261.
Google Scholar
[16]
Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ. Association between apolipoprotein E ε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998, 55(8): 1065– 1069.
DOI Google Scholar
[17]
van der Flier WM, Schoonenboom SNM, Pijnenburg YAL, Fox NC, Scheltens P. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006, 67(3): 526–527.
DOI Google Scholar
[18]
Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, Pritchard A, Lendon CL, Richardson AM, Varma A, Neary D, Mann DMA. Cognitive phenotypes in Alzheimer’s disease and genetic risk. Cortex 2007, 43(7): 835–845.
DOI Google Scholar
[19]
Marra C, Bizzarro A, Daniele A, De Luca L, Ferraccioli M, Valenza A, Brahe C, Tiziano FD, Gainotti G, Masullo C. Apolipoprotein E ε4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer’s disease patients. Dement Geriatr Cogn Disord 2004, 18(2): 125–131.
DOI Google Scholar
[20]
Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE. The role of APOE-ε4 in longitudinal cognitive decline: MacArthur studies of successful aging. Neurology 2003, 60(7):1077–1081.
DOI Google Scholar
[21]
Smith GE, Bohac DL, Waring SC, Kokmen E, Tangalos EG, Ivnik RJ, Petersen RC. Apolipoprotein E genotype influences cognitive ‘phenotype’ in patients with Alzheimer’s disease but not in healthy control subjects. Neurology 1998, 50(2): 355–362.
DOI Google Scholar
[22]
Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, Berry-Kravis E, Bach J, Fox JH, Evans DA, Bennett DA. The apolipoprotein E ε4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002, 59(7): 1154–1160.
DOI Google Scholar
[23]
Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, Burke GL, Tracy R, Bhadelia R. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 1998, 29(2): 388–398.
DOI Google Scholar
[24]
Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA. The MIRAGE Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002, 287(3): 329–336.
Google Scholar
[25]
Murrell JR, Price B, Lane KA, Baiyewu O, Gureje O, Ogunniyi A, Unverzagt FW, Smith-Gamble V, Gao S, Hendrie HC, Hall KS. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol 2006, 63(3): 431–434.
DOI Google Scholar
[26]
Hirono N, Hashimoto M, Yasuda M, Kazui H, Mori E. Accelerated memory decline in Alzheimer’s disease with apolipoprotein ε4 allele. J Neuropsychiatry Clin Neurosci 2003, 15(3): 354–358.
DOI Google Scholar
[27]
YangCH, Wu SJ, Chou MC, Chen CH, Tai SY, Huang SW, Yang YH. Effects of the Apolipoprotein E genotype on the therapeutic response in Alzheimer’s disease patients in Taiwan. J Dis Markers 2015, 2(1): 1019.
Google Scholar
[28]
van der Vlies AE, Pijnenburg YAL, Koene T, Klein M, Kok A, Scheltens P, van der Flier WM. Cognitive impairment in Alzheimer’s disease is modified by APOE genotype. Dement Geriatr Cogn Disord 2007, 24(2): 98–103.
DOI Google Scholar
[29]
El Haj M, Antoine P, Amouyel P, Lambert JC, Pasquier F, Kapogiannis D. Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer’s disease: A review. Ageing Res Rev 2016, 11(27): 15–22.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 18 January 2016
Revised: 26 February 2016
Accepted: 29 February 2016
Published: 01 March 2016
Issue date: March 2016

Copyright

© The authors 2016.

Rights and permissions

This article is published with open access at www.TNCjournal.com

Return